Cerebrofacial venous metameric syndrome —spectrum of imaging findings
AbstractCerebrofacial venous metameric syndrome (CVMS) is a complex craniofacial vascular malformation disorder in which patients have a constellation of venous vascular malformations affecting soft tissues, bone, dura, and neural structures including the eye and brain. It is hypothesized that a somatic mutation responsible for the venous abnormalities occurred prior to migration of the neural crest cells, and because of this, facial, osseous, and cerebral involvement typically follows a segmental or “metameric” distribution. The most commonly recognized form of CVMS is Sturge-Weber syndrome. However, a wide spectrum of CVMS phenotypical presentations exist with various metameric distributions of slow-flow vascular lesions including facial venous vascular malformations, developmental venous anomalies, venous angiomas, cavernous malformations (cavernomas), dural sinus malformations, and maybe even vascular tumors such as cavernous hemangiomas. Awareness of the various manifestations as described herewith is important for treatment and screening purposes.
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.
(University of Zurich) It is not always possible to completely remove malignant brain tumors by surgery so that further treatment is necessary. Researchers from the University of Zurich and the UniversityHospital Zurich have now been able to describe, with unparalleled precision, the composition of the immune cells of various types of brain tumors. This will provide an important foundation for future immunotherapy approaches.
Conclusions: Ophthalmologists should consider the diagnosis of PVRL in HIV-positive individuals who present with intermediate or posterior uveitis. PMID: 32453669 [PubMed - as supplied by publisher]
AbstractThe updated 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System (CNS) has incorporated molecular parameters into pathological diagnosis, for the first time in the molecular era. While it has led to the more precise diagnoses of well-understood entities and the better comprehension of less-understood entities, its practical application has also created some concerns whether or not genotypes predominate over phenotypes in tumor diagnostics. In response to these concerns, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy –Not Official WHO (...
AbstractTetraspanin (TSPAN) protein family forms a family of transmembrane proteins that act as organizers/scaffold for other proteins. TSPANs are primarily present on plasma membranes although they are also found in other biological membranes. They are organized in tetraspanin-enriched microdomains (TEMs), which allow spatiotemporal tuning of protein functions through the control of their membrane localization. TSPAN6 and TSPAN7 are close paralogs expressed in different tissues, TSPAN7 being highly expressed in the brain. Their functions only started to be unveiled in the late 2000 ’s and are still poorly understood...
Conclusions: The incidence of BM among patients with gynecologic malignancies is rare and associated with poor survival. For select patients, SRS may be associated with prolonged survival.
Conclusion: In GCT patients, our mBEP-schedule would suggest an effective treatment modality without suffering meaningful pulmonary toxicity.
ConclusionThese data establish that [89Zr]anti-CD11b Ab immunoPET targets CD11b+ cells (TAMCs) with high specificity in a mouse model of GBM, demonstrating the potential for non-invasive quantification of tumor-infiltrating CD11b+ immune cells during disease progression and immunotherapy in patients with GBM.
In this study, researchers investigated if specific targeting of CD133+ glioblastoma with cutting-edge immunotherapy drugs could eradicate the most aggressive subpopulation of cells in the tumor. They also looked at the safety of CD133-targeting therapies on normal, non-cancerous human stem cells including hematopoietic stem cells which create blood cells and progenitor cells which can form one or more kinds of cells.
Dear colleagues, please advise concerning this patient: 40 yo male, high PS, diagnosed a couple of years ago of colic cancer that was locally treated. Aug 2020: he was diagnosed of left parietal (at the level of the motor strip) solitary brain lesion. octobre 2020: he underwent a complete resection , followed by cavity SRS 18Gy /1 fr April 2020: refractory seizures MRI showed a relapsing left parietal cavity lesion, whose epicenter was next to the trolard vein. he was re-resected quasi... re-irradiation after single fraction cavity SRS? What dose?